Faron Pharmaceuticals Oy (LON:FARN) Stock Crosses Below 50 Day Moving Average – Time to Sell?

Faron Pharmaceuticals Oy (LON:FARN)’s stock price passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 178.14 and traded as low as GBX 166. Faron Pharmaceuticals Oy shares last traded at GBX 169.99, with a volume of 642 shares.

Faron Pharmaceuticals Oy Stock Performance

The company has a debt-to-equity ratio of 922.55, a current ratio of 1.45 and a quick ratio of 1.09. The company has a fifty day moving average price of GBX 178.14 and a 200 day moving average price of GBX 189.27. The stock has a market cap of £194.50 million, a P/E ratio of -6.30 and a beta of 0.36.

Insider Buying and Selling at Faron Pharmaceuticals Oy

In other news, insider Jurriaan Dekkers sold 4,000 shares of Faron Pharmaceuticals Oy stock in a transaction dated Monday, January 12th. The shares were sold at an average price of GBX 182, for a total transaction of £7,280. Company insiders own 4.05% of the company’s stock.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.